| Literature DB >> 35631339 |
Nikita Frolov1, Elena Detusheva2, Nadezhda Fursova2, Irina Ostashevskaya1,3, Anatoly Vereshchagin1.
Abstract
This work is devoted to the investigation of biocidal properties of quaternary ammonium compounds (QACs) based on pyridine structures with aromatic spacers, and their widely known analogs, against clinically significant microorganisms. This study is focused on investigating their antimicrobial activity (minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs)), antibiofilm properties (minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm eradication concentrations (MBECs)), synergetic effect with different alcohols in antiseptic formulations, and bacterial resistance development. It was shown that all combined analogue preparations had a higher level of antibacterial activity against the tested bacterial strains, with a 16- to 32-fold reduction in MICs and MBCs compared to previously used antiseptic preparations. Moreover, hit-QACs demonstrated a stable effect against Gram-negative E. coli, K. pneumoniae, and A. baumannii within a month of incubation. Overall results indicated a high level of antibacterial activity of pyridine-based QACs.Entities:
Keywords: antibacterial activity; antibiofilm activity; antiseptics; bacterial resistance; biocides; disinfectants; pyridinium salts; quaternary ammonium compounds
Year: 2022 PMID: 35631339 PMCID: PMC9145796 DOI: 10.3390/ph15050514
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Tested bis-QACs: hit compounds 1–2 from ref. [15], and 3 from ref. [16].
Intensity of biofilm formation by reference strains.
| Strains | OD590 | Intensity |
|---|---|---|
| 0.272 ± 0.011 | modest | |
| 0.255 ± 0.008 | modest | |
| 0.301 ± 0.008 | modest | |
| 0.383 ± 0.013 | high | |
| 0.391 ± 0.005 | high |
Intensity of biofilm formation by clinical strains.
| Strains | OD590 | Intensity |
|---|---|---|
| 0.287 ± 0.005 | modest | |
| 0.399 ± 0.011 | high | |
| 0.343 ± 0.022 | high | |
| 0.452 ± 0.018 | high | |
| 0.415 ± 0.012 | high |
Antibacterial activity of new bis-QACs against planktonic cells and biofilms.
| Compounds | MIC/MBC (mg/L) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reference Strains | Clinical Strains | |||||||||
|
|
|
|
|
|
|
|
|
|
| |
|
| ||||||||||
| 0.5 | 4 | 8 | 16 | 16 | 0.5 | 4 | 4 | 16 | 16 | |
| 4 | 8 | 8 | 16 | 63 | 4 | 16 | 8 | 16 | 16 | |
| 1 | 8 | 16 | 16 | 16 | 1 | 8 | 16 | 32 | 250 | |
| 8 | 8 | 63 | 16 | 16 | 4 | 8 | 63 | 63 | 500 | |
| 1 | 16 | 16 | 16 | 16 | 1 | 16 | 16 | 16 | 8 | |
| 8 | 32 | 16 | 16 | 16 | 4 | 63 | 16 | 16 | 63 | |
|
| 125 | 4 | 500 | >500 | >500 | 125 | 500 | 500 | >500 | >500 |
| 250 | 8 | 500 | >500 | >500 | 500 | >500 | 500 | >500 | >500 | |
|
| 4 | 8 | 63 | 32 | 500 | 2 | 8 | 8 | 16 | 32 |
| 16 | 8 | 250 | 125 | >500 | 16 | 63 | 16 | 32 | 125 | |
|
| 0.5 | 0.5 | 4 | 32 | 8 | 0.5 | 2 | 2 | 32 | 32 |
| 2 | 0.5 | 8 | 125 | 16 | 2 | 4 | 4 | 125 | 63 | |
|
| ||||||||||
| 8 | 16 | 16 | 32 | 125 | 8 | 16 | 16 | 32 | 125 | |
| 16 | 16 | 32 | 125 | 500 | 8 | 32 | 125 | 125 | 500 | |
| 4 | 16 | 16 | 250 | 125 | 8 | 32 | 16 | 32 | 250 | |
| 16 | 16 | 250 | 250 | >500 | 16 | 32 | 250 | 500 | 500 | |
| 8 | 16 | 32 | 63 | 125 | 8 | 16 | 32 | 32 | 250 | |
| 16 | 16 | 125 | 500 | >500 | 16 | 63 | 250 | 500 | >500 | |
|
| >500 | 250 | >500 | >500 | >500 | >500 | >500 | >500 | >500 | >500 |
| >500 | 250 | >500 | >500 | >500 | >500 | >500 | >500 | >500 | >500 | |
|
| 16 | 16 | 63 | 250 | >500 | 8 | 125 | 63 | 250 | >500 |
| 63 | 63 | 250 | 500 | >500 | 32 | 250 | 500 | 500 | >500 | |
|
| 4 | 8 | 16 | 250 | 125 | 4 | 16 | 16 | 32 | 250 |
| 8 | 16 | 63 | 250 | 500 | 8 | 125 | 125 | 250 | 250 | |
Antibacterial activity of QACs with different alcohols against planktonic cells.
| Compositions | MIC/MBC (mg/L) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reference Strains | Clinical Strains | |||||||||
|
|
|
|
|
|
|
|
|
|
| |
| 2 | 2 | 4 | 8 | 16 | 2 | 2 | 2 | 16 | 16 | |
| 4 | 2 | 8 | 8 | 16 | 4 | 2 | 4 | 16 | 16 | |
| 2 | 2 | 2 | 8 | 16 | 2 | 4 | 4 | 16 | 16 | |
| 4 | 2 | 4 | 16 | 32 | 4 | 4 | 4 | 16 | 63 | |
| 2 | 2 | 4 | 8 | 16 | 2 | 4 | 8 | 16 | 16 | |
| 4 | 4 | 4 | 16 | 16 | 4 | 4 | 16 | 16 | 16 | |
|
| 4 | 16 | 16 | 16 | 32 | 1 | 16 | 32 | 16 | 16 |
| 16 | 16 | 16 | 16 | 63 | 16 | 32 | 32 | 32 | 125 | |
|
| 1 | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 4 | 2 |
| 8 | 2 | 1 | 2 | 2 | 8 | 4 | 4 | 8 | 8 | |
| 125 | 32 | 63 | 16 | 16 | 250 | 63 | 125 | 16 | 32 | |
| 500 | 32 | 125 | 125 | 125 | 500 | 63 | 250 | 125 | 125 | |
| 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | |
| 1 | 2 | 2 | 2 | 4 | 1 | 2 | 2 | 2 | 2 | |
| 1 | 2 | 4 | 2 | 2 | 1 | 2 | 4 | 2 | 2 | |
| 1 | 2 | 4 | 2 | 2 | 2 | 2 | 8 | 2 | 8 | |
| 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | |
| 1 | 2 | 4 | 2 | 4 | 2 | 2 | 2 | 2 | 4 | |
|
| 4 | 8 | 4 | 8 | 32 | 1 | 16 | 32 | 16 | 16 |
| 16 | 8 | 16 | 32 | 63 | 16 | 125 | 32 | 32 | 63 | |
|
| 1 | 4 | 1 | 2 | 1 | 0.5 | 4 | 2 | 2 | 4 |
| 2 | 4 | 1 | 2 | 1 | 2 | 4 | 4 | 4 | 4 | |
| 63 | 32 | 32 | 16 | 16 | 63 | 32 | 32 | 16 | 16 | |
| 250 | 32 | 63 | 63 | 63 | 250 | 32 | 125 | 32 | 63 | |
| 2 | 2 | 2 | 0,5 | 8 | 2 | 2 | 4 | 4 | 8 | |
| 4 | 2 | 2 | 1 | 8 | 4 | 2 | 4 | 4 | 8 | |
| 2 | 2 | 2 | 2 | 8 | 2 | 4 | 2 | 4 | 8 | |
| 4 | 2 | 2 | 2 | 8 | 4 | 4 | 2 | 4 | 8 | |
| 2 | 2 | 1 | 2 | 8 | 2 | 2 | 2 | 4 | 8 | |
| 2 | 2 | 1 | 8 | 16 | 4 | 2 | 2 | 4 | 8 | |
|
| 4 | 16 | 16 | 16 | 16 | 1 | 16 | 16 | 16 | 16 |
| 16 | 16 | 16 | 16 | 63 | 16 | 16 | 32 | 32 | 63 | |
|
| 1 | 1 | 1 | 2 | 2 | 0,5 | 2 | 2 | 2 | 2 |
| 4 | 1 | 1 | 2 | 2 | 4 | 2 | 8 | 4 | 4 | |
| 16 | 32 | 63 | 16 | 16 | 63 | 63 | 125 | 16 | 16 | |
| 250 | 32 | 125 | 63 | 63 | 250 | 63 | 125 | 63 | 63 | |
Note: color indicates results that do not differ (or worse) from those of individual substances or control samples, i.e., formulation is not effective.
Antibacterial activity of QACs with different alcohols against biofilms.
| Compositions | MIC/MBC (mg/L) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reference Strains | Clinical Strains | |||||||||
|
|
|
|
|
|
|
|
|
|
| |
| 2 | 8 | 16 | 250 | 63 | 4 | 4 | 63 | 125 | 63 | |
| 2 | 16 | 32 | 250 | 63 | 4 | 4 | 63 | 125 | 125 | |
| 1 | 4 | 32 | 63 | 32 | 4 | 8 | 63 | 32 | 32 | |
| 2 | 16 | 63 | 250 | 63 | 4 | 16 | 63 | 125 | 250 | |
| 2 | 16 | 16 | 125 | 63 | 4 | 1 | 63 | 32 | 32 | |
| 2 | 32 | 63 | 500 | 250 | 8 | 16 | 125 | 125 | 125 | |
|
| 16 | 16 | 32 | 32 | 125 | 8 | 16 | 32 | 32 | 63 |
| 16 | 16 | 32 | 32 | 125 | 32 | 16 | 32 | 32 | 125 | |
|
| 1 | 4 | 8 | 16 | 16 | 2 | 4 | 16 | 16 | 16 |
| 4 | 8 | 16 | 32 | 63 | 4 | 16 | 32 | 32 | 32 | |
| 32 | 16 | 63 | 63 | 125 | 63 | 32 | 63 | 63 | 32 | |
| 63 | 32 | 125 | 250 | 125 | 125 | 63 | 125 | 125 | 125 | |
| 2 | 4 | 8 | 32 | 16 | 2 | 4 | 8 | 32 | 16 | |
| 8 | 4 | 8 | 63 | 32 | 8 | 4 | 8 | 63 | 32 | |
| 4 | 4 | 16 | 32 | 16 | 4 | 4 | 16 | 16 | 32 | |
| 8 | 4 | 32 | 32 | 32 | 8 | 4 | 63 | 32 | 32 | |
| 2 | 4 | 8 | 32 | 16 | 1 | 4 | 16 | 16 | 16 | |
| 4 | 4 | 16 | 32 | 32 | 2 | 4 | 32 | 16 | 63 | |
|
| 16 | 16 | 32 | 32 | 125 | 16 | 16 | 32 | 32 | 63 |
| 16 | 16 | 32 | 32 | 125 | 32 | 16 | 32 | 32 | 125 | |
|
| 2 | 4 | 4 | 16 | 8 | 2 | 4 | 16 | 16 | 16 |
| 2 | 8 | 8 | 32 | 32 | 4 | 4 | 32 | 32 | 32 | |
| 32 | 16 | 63 | 63 | 125 | 63 | 32 | 63 | 63 | 32 | |
| 63 | 32 | 63 | 250 | 125 | 125 | 63 | 125 | 250 | 125 | |
| 1 | 4 | 8 | 32 | 16 | 2 | 1 | 16 | 32 | 16 | |
| 2 | 4 | 16 | 63 | 63 | 4 | 4 | 32 | 32 | 63 | |
| 1 | 8 | 16 | 32 | 32 | 2 | 8 | 32 | 32 | 32 | |
| 2 | 32 | 63 | 125 | 63 | 4 | 8 | 63 | 63 | 125 | |
| 4 | 16 | 16 | 32 | 16 | 2 | 2 | 32 | 32 | 16 | |
| 4 | 16 | 16 | 63 | 63 | 4 | 4 | 32 | 63 | 63 | |
|
| 16 | 1 | 32 | 32 | 125 | 16 | 1 | 32 | 32 | 63 |
| 16 | 2 | 32 | 63 | 250 | 32 | 8 | 32 | 32 | 500 | |
|
| 1 | 2 | 8 | 8 | 16 | 2 | 2 | 16 | 16 | 16 |
| 4 | 4 | 8 | 16 | 63 | 4 | 8 | 16 | 32 | 125 | |
| 32 | 16 | 63 | 63 | 125 | 32 | 32 | 63 | 63 | 32 | |
| 63 | 32 | 63 | 125 | 125 | 125 | 63 | 125 | 125 | 125 | |
Note: color indicates results that do not differ (or worse) from those of individual substances or control samples, i.e., formulation is not effective.
Effectivity of antiseptic compositions.
| Compositions | Effectivity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference Strains | Clinical Strains | Σ | |||||||||
|
|
|
|
|
|
|
|
|
|
| ||
|
| |||||||||||
|
| 40% | 80% | 90% | 70% | 40% | 20% | 80% | 70% | 40% | 70% | 60% |
|
| 50% | 80% | 100% | 100% | 80% | 60% | 80% | 70% | 80% | 80% |
|
|
| 50% | 80% | 100% | 90% | 80% | 30% | 90% | 70% | 90% | 80% |
|
|
| |||||||||||
|
| 100% | 50% | 70% | 40% | 90% | 100% | 100% | 60% | 60% | 20% | 69% |
|
| 90% | 90% | 90% | 90% | 80% | 100% | 100% | 90% | 100% | 80% |
|
|
| 100% | 70% | 90% | 80% | 80% | 100% | 100% | 60% | 70% | 50% | 80% |
Figure 2Resistance study. Graphs show the growth of QACs bactericidal concentrations with increasing incubation time on each pathogen.